Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New class of small-molecule MCH-R1 antagonists reported by Schering-Plough

Aug. 27, 2007

Novel SARMs designed by Merck as potential osteoanabolic agents

Aug. 27, 2007

First patients enrolled in AtheroGenics phase III diabetes trial of AGI-1067

Aug. 27, 2007

New treatments for gynecological disorders disclosed in recent Lilly patent

Aug. 27, 2007

Teijin and Chugai agree to codevelop Ipsen's antidiabetic medicine in Japan

Aug. 27, 2007

Patient enrollment in phase III trial of QUATRx's Ophena completed

Aug. 27, 2007

Potent and selective PPARalpha activator emerges from SAR program at BMS

Aug. 27, 2007

Series of nonsteroidal SARMs discovered at GSK

Aug. 27, 2007

Promising 11beta.-HSD1 inhibitor with potential in endocrine and metabolic disorders

Aug. 23, 2007

SARMs designed at BMS with selectivity for muscle over prostate

Aug. 23, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal
BioWorld
In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...
News in brief
BioWorld Asia
BioWorld Asia briefs for May 12, 2026
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...